Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Zhejiang Hisun Pharmaceutical Co. Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 2 distinct examiners, both of whom are located within 1 distinct art unit. This indicates that while the workload is spread across multiple individuals, the technical focus remains concentrated within a single examination group. OH, TAYLOR V is identified as the busiest examiner, holding 1 pending office action.
Because each of the examiners holds the same amount of work, the workload is evenly distributed across the assigned staff. Practitioners should note the examiner-to-art-unit ratio, which may lead to different interpretations of similar technology within the same group. The presence of 2 pending actions suggests an active prosecution phase. Navigating different examiners within the assigned art unit requires a strategy that accounts for the specific preferences of each individual while maintaining consistency across the Biotechnology & Pharmaceuticals filings. This structure allows for a focused technical review while benefiting from the perspectives of multiple examiners within a single technical group.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OH, TAYLOR V | 1 | 81.2% | +15.3% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18865580 | Crystal Forms Of HS378 And Preparation Method Therefor | OH, TAYLOR V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18865580 | Crystal Forms Of HS378 And Preparation Method Therefor | OH, TAYLOR V | — |
| 18571213 | SALT OF SELECTIVE FGFR4 INHIBITOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18865580 | Crystal Forms Of HS378 And Preparation Method Therefor | OH, TAYLOR V | — | §103 | Non-Final OA | — | Pending | Nov 13, 2024 |
| 18571213 | SALT OF SELECTIVE FGFR4 INHIBITOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WHITE, DAWANNA SHAR-DAY | 1627 | §103DP | Final Rejection | — | Pending | Dec 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial